Joint detection method of fusion genes related to leukemia and diagnosis kit

Abstract

The invention discloses a joint detection method of fusion genes related to leukemia and a diagnosis kit. The method comprises the following steps of: designing a primer and a probe through a fusion gene mRNA (the fusion genes related to the leukemia are SIL-TAL1(type II, type III), MLL-AF4(e9 / e5,e9 / e4) and CBFB-MYH11(type D)) related to the leukemia; hybridizing a probe and microsphere mixture formed by the covalent bonding of the probe and microspheres with an RT-PCR (Reverse Transcription-Polymerase Chain Reaction) amplification product; and adding phycoerythrin as streptavidin biotin to detect fluorescent signals of different microspheres so as to confirm whether a sample to be detected contains a leukemia fusion gene as well as the expression conditions of the fusion gene. The method and the kit of the invention have the advantages of high sensitivity and flux, rapid and accurate detection, and the like and can be used for simultaneously, qualitatively and quantitatively detecting various leukemia fusion genes.

Description

technical field [0001] The invention relates to the technical field of in vitro diagnosis and detection, in particular to a liquid phase chip joint detection method and a diagnostic kit for multiple fusion genes related to leukemia. Background technique [0002] Leukemia is a malignant tumor of the hematopoietic system caused by abnormal differentiation and malignant proliferation of hematopoietic stem cells. It is one of the most common malignant tumors in my country. With the continuous progress of leukemia research, it has been found that many leukemia patients have specific chromosomal translocations, leading to the generation of new fusion genes, and these abnormal genes have become molecular biology-specific markers of different types of leukemia. In 2000, WHO's criteria for leukemia classification included some common abnormal genes as the criteria for the basic diagnosis of leukemia. Therefore, the detection of leukemia-related fusion genes at the molecular gene lev...

AI Technical Summary

Problems solved by technology

Immunological methods have high false positive and false negative rates, and cannot achieve early diagnosis

Among the molecular biology methods widely used at home and abroad to detect leukemia fusion genes, fluorescence in situ hybridization (FISH) can only perform qualitative detection, and the operation is complicated; fluorescent quantitative PCR has limitations in detection throughput, so none of them can Really meet the needs of clinical diagnostic testing

The traditional solid-phase biochip (Biochip) technology has outstanding weaknesses such as poor repeatability, insufficient sensitivity, and cumbersome operations.

Images